Literature DB >> 15616875

Chemoradiotherapy for pancreatic cancer: current status and perspectives.

Natsuo Oya1.   

Abstract

The poor prognosis of pancreatic cancer is due to both its metastasis-prone and locally resistant nature. To improve therapeutic outcome, a multimodality approach is necessary. Chemoradiotherapy has been regarded as one of the standard treatment options, particularly for locally advanced pancreatic cancer. A number of clinical studies have been undertaken to establish the use of chemoradiotherapy, with or without surgical resection. This review systematically summarizes the current status, controversies, and prospects of postoperative, definitive, and preoperative chemoradiotherapy for pancreatic cancer.

Entities:  

Mesh:

Year:  2004        PMID: 15616875     DOI: 10.1007/s10147-004-0449-6

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  4 in total

1.  Prognostic value of SUVmax measured by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography in Patients with Pancreatic Cancer.

Authors:  Jae Pil Hwang; Ilhan Lim; Kyoung Jin Chang; Byung Il Kim; Chang Woon Choi; Sang Moo Lim
Journal:  Nucl Med Mol Imaging       Date:  2012-06-30

2.  Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma.

Authors:  Jona A Hattangadi; Theodore S Hong; Beow Y Yeap; Harvey J Mamon
Journal:  Cancer       Date:  2009-08-15       Impact factor: 6.860

3.  Evaluation of a gene-directed enzyme-product therapy (GDEPT) in human pancreatic tumor cells and their use as in vivo models for pancreatic cancer.

Authors:  Juraj Hlavaty; Helga Petznek; Harry Holzmüller; Angelika Url; Gerrit Jandl; André Berger; Brian Salmons; Walter H Günzburg; Matthias Renner
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

4.  [6]-Gingerol induces cell cycle arrest and cell death of mutant p53-expressing pancreatic cancer cells.

Authors:  Yon Jung Park; Jing Wen; Seungmin Bang; Seung Woo Park; Si Young Song
Journal:  Yonsei Med J       Date:  2006-10-31       Impact factor: 2.759

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.